Independent experts voted 10-3 despite regulators’ concern about the design of the company’s pivotal cancer trial.
Source link
About The Author
A Food and Drug Administration advisory panel voted 10-3 for Replimune Group’s experimental melanoma therapy, after experts raised doubts about whether the company’s data and trial design could be trusted to show the drug works